Table 4.
The distribution of antimicrobial-resistant E. coli in the age groups ≤3 and >80 in 2009–2010 and 2020.
| Age Group (Years Old) in 2009–2010 |
Age Group (Years Old) in 2020 |
p-Value | ||||||
|---|---|---|---|---|---|---|---|---|
| Antimicrobial Category and Agents | ≤3 (n = 75) |
>80 (n = 89) | p-Value | ≤3 (n = 60) |
>80 (n = 67) | p-Value | ≤3 Age Group a | >80 Age Group b |
| I + R | I + R | I + R | I + R | |||||
| Aminoglycoside | ||||||||
| AN | 1 (1.3) | 2 (2.2) | 0.664 | 0 (0) | 1 (1.5) | 0.342 | 0.369 | 0.734 |
| GM | 25 (33.3) | 25 (28.1) | 0.467 | 17 (28.3) | 14 (20.9) | 0.330 | 0.533 | 0.304 |
| Penicillins | ||||||||
| AM | 62 (82.7) | 74 (83.1) | 0.935 | 44 (73.3) | 51 (76.1) | 0.718 | 0.189 | 0.276 |
| AMC | 17 (22.7) | 38 (42.7) | 0.007 | 16 (26.7) | 22 (32.8) | 0.448 | 0.591 | 0.210 |
| Penicillins + β-lactamase inhibitors | ||||||||
| SAM | 14 (18.7) | 39 (43.8) | 0.001 | 12 (20.0) | 19 (28.4) | 0.274 | 0.845 | 0.048 |
| TZP | 1 (1.3) | 6 (6.7) | 0.088 | 0 (0) | 2 (3.0) | 0.177 | 0.369 | 0.292 |
| Carbapenems | ||||||||
| IPM | 0 (0) | 0 (0) | - | 0 (0) | 2 (3.0) | 0.177 | - | 0.101 |
| ETP | 1 (1.3) | 2 (2.2) | 0.664 | 0 (0) | 0 (0) | - | 0.369 | 0.217 |
| MEM | 1 (1.3) | 1 (1.1) | 0.903 | 0 (0) | 1 (1.5) | 0.342 | 0.369 | 0.839 |
| Non-extended spectrum cephalosporins |
||||||||
| CZ | 15 (20.0) | 39 (43.8) | 0.001 | 15 (25.0) | 31 (46.3) | 0.013 | 0.487 | 0.761 |
| CXM | 15 (20.0) | 37 (41.6) | 0.003 | 14 (23.3) | 28 (41.8) | 0.027 | 0.639 | 0.978 |
| CMZ | 2 (2.7) | 22 (24.7) | <0.001 | 1 (1.7) | 6 (9.0) | 0.072 | 0.695 | 0.011 |
| Extended-spectrum cephalosporins |
||||||||
| CRO | 16 (21.3) | 37 (41.6) | 0.006 | 14 (23.3) | 31 (46.3) | 0.007 | 0.781 | 0.558 |
| CAZ | 12 (16.0) | 31 (34.8) | 0.006 | 10 (16.7) | 16 (23.9) | 0.314 | 0.917 | 0.140 |
| FEP | 9 (12.0) | 19 (21.3) | 0.113 | 10 (16.7) | 15 (22.4) | 0.418 | 0.438 | 0.876 |
| Cephamycins | ||||||||
| FOX | 8 (10.7) | 30 (33.7) | <0.001 | 3 (4.9) | 9 (13.4) | 0.105 | 0.232 | 0.004 |
| Fluoroquinolones | ||||||||
| CIP | 20 (26.7) | 51 (57.3) | <0.001 | 20 (33.3) | 39 (58.2) | 0.005 | 0.399 | 0.910 |
| LVX | 15 (20.0) | 43 (48.3) | <0.001 | 16 (26.7) | 36 (53.7) | 0.002 | 0.360 | 0.503 |
| Tetracyclines | ||||||||
| TE | 46 (61.3) | 52 (58.4) | 0.705 | 29 (48.3) | 33 (49.3) | 0.917 | 0.131 | 0.255 |
| Glycylcyclines | ||||||||
| TIG | 0 (0) | 0 (0) | - | 0 (0) | 0 (0) | - | - | - |
| Folate pathway inhibitors | ||||||||
| SXT | 41 (54.7) | 54 (60.7) | 0.438 | 32 (53.3) | 24 (35.8) | 0.047 | 0.877 | 0.002 |
| Drug-resistance | 0.052 | 0.145 | 0.467 | 0.855 | ||||
| MDR | 39 (52.0) | 57 (64.0) | 36 (60.0) | 40 (59.7) | ||||
| XDR | 1 (1.3) | 5 (5.6) | 0 (0) | 4 (6.0) | ||||
a Statistical results for the distribution of virulence factors in patient age group ≤3 years old in 2009–2010 compared to 2020. b Statistical results for the distribution of virulence factors in patient age group >80 years old in 2009–2010 compared to 2020. Abbreviations: AM, ampicillin; AMC, amoxicillin; AN, amikacin; CAZ ceftazidime, CIP, ciprofloxacin; CMZ, cefmetazole; CRO, ceftriaxone; CXM, cefuroxime; CZ, cefazolin; ETP, ertapenem; FEP, cefepime; FOX, cefoxitin; GM, gentamicin; LVX, levofloxacin; IPM, imipenem; MEM meropenem; SAM, ampicillin/sulbactam; SXT, sulfamethoxazole/trimethoprim; TE, tetracycline; TIG, tigecycline; TZP, piperacillin/tazobactam; I, intermediate resistant; R, resistant; MDR, multidrug-resistant; XDR, extensively drug-resistant.